Cavli Wireless to Reveal the Ultra Low-Cost CAT1.bis Module C16QS at Embedded World 2023 Germany
Cavli Wireless is set to attend the Embedded World 2023 edition in Nuremberg, Germany, from March 14-16, 2023. The event is known for being the largest trade fair for Embedded technology, showcasing various electronic systems, distributed intelligence, IoT, energy efficiency, and more. Cavli will showcase its IoT connectivity solutions in Hall 3, Booth 3-328.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005787/en/
Introducing The Cavli C16QS - The World's Most Affordable LTE CAT1.bis Cellular IoT Module @ EW23 (Graphic: Business Wire)
The premier showcase at the Cavli booth will be the newly launched Cavli C16QS, an integrated single-mode LTE CAT1.bis Cellular Module based on 3GPP Release 14, which comes with an integrated eSIM and GNSS. The Cavli C16QS will also offer OEMs implementing IoT to cut down initial hardware costs due to the efficient pricing of the module, which makes it the world’s most affordable LTE CAT1.bis solution in the market. The integrated eSIM coupled with Cavli Hubble Global Connectivity ensures the module can be deployed globally, making it an ideal solution for logistics, automotive, vehicle tracking, and much more.
The Hubble Stack Intelligence enables remote diagnosis, monitoring, and debugging of the C16QS through Hubble Lens, an advanced remote diagnosis feature of the Cavli Hubble IoT platform. This feature eliminates the need for physical intervention, making it possible to scale IoT efficiently. And through its robust operator partnerships in the EU, Cavli has achieved an extensive presence across Europe with its local LTE and LTE-M connectivity solutions, setting new industry standards in service quality and pricing.
Cavli Wireless will also be exhibiting the flagship C-Series Cellular IoT modules featuring LPWAN and Wideband connectivity with a wide range of options in terms of footprint, power consumption, and network capabilities, which makes Cavli Smart Modules an apt choice for any solution customers wish to implement. The Cavli solution expertise team will also be featuring live demos of the Hubble Tech Stack and free solution consulting to the booth visitors. The attendees can book a meeting with the consulting team here: https://www.cavliwireless.com/engagements/product-and-solution-guides.html
"As the primary trade event for technology companies worldwide, Embedded World 2023 provides the perfect platform for unveiling our industry-leading Cellular IoT solutions. Cavli Wireless is excited to join industry leaders in this prestigious event and demonstrate our commitment to democratizing the Internet of Things," commented, Tarun Thomas George, Chief Operating Officer, Cavli Wireless.
About Cavli Wireless
Cavli Wireless is a cellular IoT module manufacturer that combines IoT connectivity and data management into one platform. Cavli designs and manufactures industrial-grade cellular IoT smart modules that improve equipment reliability and expedite application development processes. Cavli's smart cellular modules are equipped with global cellular connectivity through integrated eSIM functionality that provides users with affordable global data pricing, simplified device management, and centralized subscription management through the proprietary cloud-based platform Cavli Hubble.
About Embedded World
Every year, the Embedded world Exhibition&Conference in Nuremberg offers the embedded community the opportunity to find out about innovations, exchange ideas, and maintain and establish valuable contacts. Exhibitors present state-of-the-art on all facets of embedded technologies, from components, modules, and complete systems to operating systems and software, hardware and software tools, and services related to embedded systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005787/en/
Contact information
Ajit Thomas, CMO, Cavli Inc
ajit@cavliwireless.com
+1-650-535-1150
https://www.cavliwireless.com/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom